Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT in TRD; Psilocybin for Smoking Cessation Study Published
Bulletin
The leading independent,
data-driven voice in psychedelics.
Explore
Insights, delivered.
Join thousands of psychedelic insiders…
By signing up, you agree to our privacy policy. You can unsubscribe at any time.
For in-depth analysis and insights, consider our premium offering: learn more about
Referenced by
Pharmaceuticals & Healthcare
We support drug developers and healthcare organisations navigating the development and delivery of psychedelic medicines.
- Leading coverage of the field ↗
- Competitive landscaping
- Exclusive interviews with KOLs
- Advisory and consultancy services ↗
Funders & Philanthropies
We provide investors and philanthropists with clear, independent insight into the psychedelic ecosystem.
- Sector trends, timelines, and data ↗
- Pipeline tracking
- Policy and regulatory analysis
- Advisory and consultancy services ↗
Researchers & Practitioners
We help researchers and practitioners make sense of the emerging ecosystem of psychedelic study and practice.
- Coverage of research trends
- Curation of job opportunities ↗
- Interviews and opinions
- The Psychedelic
Practitioner ↗
Trackers
Our trackers offer data on key areas of the psychedelic field, including drug development pipelines and policy reform activity.
Legal Map
Our Psychedelic Legalization & Decriminalization Tracker charts psychedelics-related policy reforms across the U.S.
Library
A curated library of primers covering salient topics in psychedelic science, policy, and industry.
Job Board
Our job board features roles across the psychedelics field. Join our talent pool to stay abreast of opportunities.
The Pipeline
Our Psychedelic Drug Development Tracker offers an overview of the psychedelic medicine pipeline.
Start Here
A brief introduction to psychedelic drug development, policy and access. Coming soon: join our newsletter to be the first to explore.
Pα+
An insider’s guide to the business,
policy and science of psychedelics.
Basic
Free subscribers receive a weekly round-up
of news on psychedelics, as well as the occasional article.
Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.
Teams
Teams, groups and corporate pricing plans are available, please get in touch via email
to learn more.
Benefits
Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete
archive and Library.
Learn More| Free | ||
|---|---|---|
| Weekly Psychedelic News Feed | ||
| Occasional Articles & Free Resources | ||
| Psychedelic Bulletins (In-Depth Briefings, Multiple per Month) | ||
| Quick-Take Analysis of Major Developments | ||
| In-Depth Articles & Deep Dives | ||
| Exclusive Interviews with Insiders & KOLs | ||
| Quarterly Video Briefings | ||
| Exclusive Tools & Data Resources | ||
| Library of Primers & Explainers | ||
|
Subscribe Now |
||